Fennec Pharmaceuticals Inc. (TSX:FRX)
Canada · Delayed Price · Currency is CAD | Market Cap | 336.85M +56.5% |
| Revenue (ttm) | 61.21M -6.1% |
| Net Income | -13.36M |
| EPS | -0.47 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 80.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 373 |
| Average Volume | 1,550 |
| Open | 9.70 |
| Previous Close | 9.65 |
| Day's Range | 9.58 - 9.70 |
| 52-Week Range | 7.59 - 13.83 |
| Beta | 0.91 |
| RSI | 53.67 |
| Earnings Date | May 14, 2026 |
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of oto... [Read more]
Financial Performance
In 2025, Fennec Pharmaceuticals's revenue was $44.64 million, a decrease of -6.09% compared to the previous year's $47.54 million. Losses were -$9.74 million, 2134.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Fennec Pharmaceuticals to Report First Quarter 2026 Financial Results on May 14, 2026
RESEARCH TRIANGLE PARK, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center
~ University of Arizona Cancer Center Initiating Study to Explore Use of PEDMARK ® in AYA & Adult Patients with Solid Tumors Receiving Cisplatin ~
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., March 31, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced th...
Fennec Pharmaceuticals Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
San Diego, California--(Newsfile Corp. - March 24, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Fennec Pharmaceuticals Inc. (NASDAQ: FENC). The investigatio...
Fennec Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 sales and robust AYA growth drove a 50% revenue increase, supported by expanded teams, new clinical evidence, and a strengthened balance sheet. U.S. exclusivity for PEDMARK is secured through 2033, with major European launches and further growth expected in 2026.
Fennec reports Q4 EPS (17c), consensus 4c
Reports Q4 revenue $13.78M, consensus $14.73M. “Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec (FENC) into…
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 75%...
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...
Fennec announces settlement agreement resolving Pedmark litigation
Fennec (FENC) Pharmaceuticals announces that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla’s application to FDA for…
Fennec announces clinical research collaboration with Tampa General Hospital
Fennec (FENC) Pharmaceuticals announced that the Tampa General Hospital Cancer Institute is initiating a study evaluating the real-world clinical utility of sodium thiosulfate injection in reducing th...
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-Me...
Fennec presents real world date on use of Pedmark
Fennec (FENC) Pharmaceuticals announced new real world data supporting potential use of Pedmark in adults with head and neck cancers were presented as a digital poster at the 2026 Multidisciplinary…
Fennec initiated with a Buy at B. Riley
B. Riley initiated coverage of Fennec (FENC) with a Buy rating and $16 price target The firm believes the Street is “materially” undervaluing the duration and potential expansion of Pedmark’s…
Fennec initiated with an Overweight at Piper Sandler
Piper Sandler analyst David Amsellem last night initiated coverage of Fennec (FENC) with an Overweight rating and $18 price target The firm says the company’s Pedmark, its intravenous formulation of…
Fennec initiated with an Overweight at Piper Sandler
Piper Sandler initiated coverage of Fennec (FENC) with an Overweight rating and $18 price target
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on Dec...
Fennec announces planned initiation of IST by City of Hope to evaluate PEDMARK
Fennec (FENC) Pharmaceuticals announced the planned initiation of an investigator-sponsored study, IST, by City of Hope, a U.S. cancer research and treatment organization, to evaluate PEDMARK for the ...
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
Fennec Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
PEDMARK, the only FDA-approved therapy for cisplatin-induced ototoxicity in pediatric and AYA patients, is expanding its market reach with strong sales growth, broad payer coverage, and new data supporting efficacy and safety. European and Japanese launches are underway, with ongoing efforts to expand indications and awareness.
Fennec announces Phase 2/3 STS-J01 trial met primary endpoint
Fennec (FENC) Pharmaceuticals announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK for the reduction of cisplatin-induced ototoxicity ...
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates o...
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...
Fennec completes full debt redemption
Fennec (FENC) Pharmaceuticals has repurchased and redeemed all of Fennec’s outstanding convertible notes issued to Petrichor Opportunities Fund I LP and Petrichor Opportunities Fund I Intermediate LP ...
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the...
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced tha...